These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 39097182)

  • 1. Clinical and radiological response of Maffucci related enchondromas to mutant IDH1 inhibitor Ivosidenib.
    Funck-Brentano T; Cohen-Solal M; Ducray F; Mandonnet E
    Bone; 2024 Nov; 188():117221. PubMed ID: 39097182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. IDH1 immunohistochemistry reactivity and mosaic IDH1 or IDH2 somatic mutations in pediatric sporadic enchondroma and enchondromatosis.
    Saiji E; Pause FG; Lascombes P; Cerato Biderbost C; Marq NL; Berczy M; Merlini L; Rougemont AL
    Virchows Arch; 2019 Nov; 475(5):625-636. PubMed ID: 31240473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Molecular profiling of different glioma specimens from an Ollier disease patient suggests a multifocal disease process in the setting of IDH mosaicism.
    Tan CL; Vellayappan B; Wu B; Yeo TT; McLendon RE
    Brain Tumor Pathol; 2018 Oct; 35(4):202-208. PubMed ID: 30159860
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatic IDH1 mutation in a pituitary adenoma of a patient with Maffucci syndrome.
    Hao S; Hong CS; Feng J; Yang C; Chittiboina P; Zhang J; Zhuang Z
    J Neurosurg; 2016 Jun; 124(6):1562-7. PubMed ID: 26473790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maffucci syndrome complicated by three different central nervous system tumors sharing an IDH1 R132C mutation: case report.
    Nejo T; Tanaka S; Ikemura M; Nomura M; Takayanagi S; Shin M; Ushiku T; Shibahara J; Saito N; Mukasa A
    J Neurosurg; 2019 Dec; 131(6):1829-1834. PubMed ID: 30579273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ivosidenib, an IDH1 inhibitor, in a patient with recurrent,
    Tejera D; Kushnirsky M; Gultekin SH; Lu M; Steelman L; de la Fuente MI
    CNS Oncol; 2020 Sep; 9(3):CNS62. PubMed ID: 32716208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome.
    Pansuriya TC; van Eijk R; d'Adamo P; van Ruler MA; Kuijjer ML; Oosting J; Cleton-Jansen AM; van Oosterwijk JG; Verbeke SL; Meijer D; van Wezel T; Nord KH; Sangiorgi L; Toker B; Liegl-Atzwanger B; San-Julian M; Sciot R; Limaye N; Kindblom LG; Daugaard S; Godfraind C; Boon LM; Vikkula M; Kurek KC; Szuhai K; French PJ; Bovée JV
    Nat Genet; 2011 Nov; 43(12):1256-61. PubMed ID: 22057234
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Somatic mosaic mutations of IDH1 and NPM1 associated with cup-like acute myeloid leukemia in a patient with Maffucci syndrome.
    Akiyama M; Yamaoka M; Mikami-Terao Y; Ohyama W; Yokoi K; Arakawa Y; Takita J; Suzuki H; Yamada H
    Int J Hematol; 2015 Dec; 102(6):723-8. PubMed ID: 26508204
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maffucci syndrome and neoplasms: a case report and review of the literature.
    Prokopchuk O; Andres S; Becker K; Holzapfel K; Hartmann D; Friess H
    BMC Res Notes; 2016 Feb; 9():126. PubMed ID: 26920730
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Abou-Alfa GK; Macarulla T; Javle MM; Kelley RK; Lubner SJ; Adeva J; Cleary JM; Catenacci DV; Borad MJ; Bridgewater J; Harris WP; Murphy AG; Oh DY; Whisenant J; Lowery MA; Goyal L; Shroff RT; El-Khoueiry AB; Fan B; Wu B; Chamberlain CX; Jiang L; Gliser C; Pandya SS; Valle JW; Zhu AX
    Lancet Oncol; 2020 Jun; 21(6):796-807. PubMed ID: 32416072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Rare Co-Occurrence of Maffucci Syndrome and Astrocytoma with IDH1 R132H Mutation: A Case Report.
    Ashirov N; Mammadinova I; Moldabekov A; Zhetpisbaev B; Teltayev D; Ryskeldiyev N; Akshulakov S
    Medicina (Kaunas); 2023 May; 59(6):. PubMed ID: 37374260
    [No Abstract]   [Full Text] [Related]  

  • 12. IDH1 R132C and ERC2 L309I Mutations Contribute to the Development of Maffucci's Syndrome.
    Cheng P; Chen K; Zhang S; Mu KT; Liang S; Zhang Y
    Front Endocrinol (Lausanne); 2021; 12():763349. PubMed ID: 34790172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating ivosidenib for the treatment of acute myeloid leukemia.
    Donker ML; Ossenkoppele GJ
    Expert Opin Pharmacother; 2020 Dec; 21(18):2205-2213. PubMed ID: 32808831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ivosidenib for the treatment of isocitrate dehydrogenase-1 mutant cholangiocarcinoma.
    Corrigan L; Lowery M
    Expert Rev Gastroenterol Hepatol; 2021 May; 15(5):475-481. PubMed ID: 33836133
    [No Abstract]   [Full Text] [Related]  

  • 15. Supratentorial multifocal gliomas associated with Ollier disease harboring IDH1 R132H mutation: A case report.
    Ikeda H; Yamaguchi S; Ishi Y; Wakabayashi K; Shimizu A; Kanno-Okada H; Endo T; Ota M; Okamoto M; Motegi H; Iwasaki N; Fujimura M
    Neuropathology; 2023 Oct; 43(5):413-420. PubMed ID: 36942363
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical development of IDH1 inhibitors for cancer therapy.
    Zarei M; Hue JJ; Hajihassani O; Graor HJ; Katayama ES; Loftus AW; Bajor D; Rothermel LD; Vaziri-Gohar A; Winter JM
    Cancer Treat Rev; 2022 Feb; 103():102334. PubMed ID: 34974243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Approval Summary: Ivosidenib for Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase-1 Mutation.
    Norsworthy KJ; Luo L; Hsu V; Gudi R; Dorff SE; Przepiorka D; Deisseroth A; Shen YL; Sheth CM; Charlab R; Williams GM; Goldberg KB; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jun; 25(11):3205-3209. PubMed ID: 30692099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical pharmacokinetics and pharmacodynamics of ivosidenib, an oral, targeted inhibitor of mutant IDH1, in patients with advanced solid tumors.
    Fan B; Mellinghoff IK; Wen PY; Lowery MA; Goyal L; Tap WD; Pandya SS; Manyak E; Jiang L; Liu G; Nimkar T; Gliser C; Prahl Judge M; Agresta S; Yang H; Dai D
    Invest New Drugs; 2020 Apr; 38(2):433-444. PubMed ID: 31028664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differentiation syndrome during ivosidenib treatment with immunohistochemistry showing isocitrate dehydrogenase R132H mutation.
    Tabata MM; Chase M; Kwong BY; Novoa RA; Fernandez-Pol S
    J Cutan Pathol; 2020 Nov; 47(11):1042-1045. PubMed ID: 32588467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of the HIF-1 pathway in individuals with Ollier disease and Maffucci syndrome.
    Poll SR; Martin R; Wohler E; Partan ES; Walek E; Salman S; Groepper D; Kratz L; Cernach M; Jesus-Garcia R; Haldeman-Englert C; Choi YJ; Morris CD; Cohen B; Hoover-Fong J; Valle D; Semenza GL; Sobreira NLM
    PLoS Genet; 2022 Dec; 18(12):e1010504. PubMed ID: 36480544
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.